black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.
Company profile
Ticker
BDTX
Exchange
Website
CEO
David M. Epstein
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Exelixis • Acorda Therapeutics ...
Former names
Aset Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Black Diamond Therapeutics (Canada) Inc. • Black Diamond Therapeutics Security Corporation ...
BDTX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Black Diamond Therapeutics Announces CEO Transition
18 Sep 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
11 Aug 23
8-K
Entry into a Material Definitive Agreement
30 Jun 23
424B5
Prospectus supplement for primary offering
30 Jun 23
424B5
Prospectus supplement for primary offering
29 Jun 23
8-K
Regulation FD Disclosure
27 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
16 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
9 May 23
Latest ownership filings
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 43.12 mm | 43.12 mm | 43.12 mm | 43.12 mm | 43.12 mm | 43.12 mm |
| Cash burn (monthly) | (no burn) | 1.16 mm | 6.68 mm | 7.13 mm | 4.79 mm | 6.07 mm |
| Cash used (since last report) | n/a | 3.19 mm | 18.38 mm | 19.63 mm | 13.18 mm | 16.70 mm |
| Cash remaining | n/a | 39.92 mm | 24.74 mm | 23.49 mm | 29.93 mm | 26.41 mm |
| Runway (months of cash) | n/a | 34.4 | 3.7 | 3.3 | 6.3 | 4.4 |
Institutional ownership, Q2 2023
| 13F holders | Current |
|---|---|
| Total holders | 77 |
| Opened positions | 34 |
| Closed positions | 9 |
| Increased positions | 13 |
| Reduced positions | 14 |
| 13F shares | Current |
|---|---|
| Total value | 197.13 bn |
| Total shares | 55.36 mm |
| Total puts | 64.10 k |
| Total calls | 366.20 k |
| Total put/call ratio | 0.2 |
| Largest owners | Shares | Value |
|---|---|---|
| BLVGF Bellevue | 8.14 mm | $41.09 bn |
| BBBOF BB Biotech | 5.38 mm | $0.00 |
| NEA Management | 4.45 mm | $22.47 bn |
| Versant Venture Capital VI | 4.33 mm | $145.19 mm |
| Ra Capital Management | 3.53 mm | $17.81 bn |
| New Enterprise Associates 16 | 3.45 mm | $131.05 mm |
| Artal | 2.05 mm | $10.34 mm |
| Boxer Capital | 2.01 mm | $10.16 bn |
| Point72 Asset Management | 2.00 mm | $10.10 bn |
| Deerfield Management | 1.80 mm | $9.09 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 17 Sep 23 | Velleca Mark A. | Stock Option Common Stock | Grant | Acquire A | No | No | 3.55 | 1,000,000 | 3.55 mm | 1,000,000 |
| 15 Sep 23 | Velleca Mark A. | Common Stock | Grant | Acquire A | No | No | 3.6 | 5,208 | 18.75 k | 46,522 |
| 15 Sep 23 | Dixon Wendy L | Common Stock | Grant | Acquire A | No | No | 3.6 | 2,986 | 10.75 k | 30,758 |
| 15 Sep 23 | Behbahani Ali | Common Stock | Grant | Acquire A | No | No | 3.6 | 3,299 | 11.88 k | 44,069 |
| 30 Jun 23 | Growth N V Biotech | Common Stock | Buy | Acquire P | No | No | 5 | 1,000,000 | 5.00 mm | 8,117,839 |
| 27 Jun 23 | David M. Epstein | Common Stock | Sell | Dispose S | No | Yes | 6.7 | 25,000 | 167.50 k | 671,423 |
News
10 Health Care Stocks Whale Activity In Today's Session
18 Sep 23
What 6 Analyst Ratings Have To Say About Black Diamond Therapeutic
12 Sep 23
Wedbush Reiterates Outperform on Black Diamond Therapeutic, Maintains $10 Price Target
12 Sep 23
Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
11 Sep 23
Black Diamond Therapeutic Q2 EPS $(0.52) Beats $(0.54) Estimate. Cash and Equivalents $89.5M
11 Aug 23
Press releases
Black Diamond Therapeutics Announces CEO Transition
18 Sep 23
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
5 Sep 23
Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
11 Aug 23
Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock
29 Jun 23
Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock
28 Jun 23